A recent study by Song et al. uncovers the role of phosphoenolpyruvate (PEP) as an innate immune checkpoint that inhibits cyclic GMP–AMP synthase (cGAS), linking metabolic changes to aging-related inflammation and neurodegeneration. The research highlights how PEP levels fluctuate during aging, ultimately collapsing and contributing to the phenomenon of inflammaging, which is characterized by chronic, low-grade inflammation that exacerbates age-related diseases.

This finding is significant for the longevity and healthspan fields as it provides a metabolic framework for understanding the onset of age-related inflammatory processes. By identifying PEP as a key regulator of cGAS activity, the study opens avenues for potential therapeutic interventions targeting metabolic pathways to mitigate aging-related inflammation and neurodegeneration.

One key takeaway is that manipulating PEP levels or its signaling pathways may offer new strategies for combating inflammaging and enhancing healthspan, underscoring the importance of metabolic health in aging research.

Source: nature.com